Prot #GSK 204862: TANGO: A Phase III, Randomized, Multicenter, Parallel-Group, Non-Inferiority Study Evaluating the Efficacy, safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed

Project: Research project

Project Details

StatusFinished
Effective start/end date4/4/18 → 4/4/21

Funding

  • PPD Investigator Services, LLC (Prot #GSK 204862)
  • GlaxoSmithKline LLC (Prot #GSK 204862)